by MM360 Staff | Dec 15, 2025 | Publications
Curr Res Transl Med. 2025 Dec 2;74(1):103559. doi: 10.1016/j.retram.2025.103559. Online ahead of print. ABSTRACT BACKGROUND: Treatment of transplant-ineligible newly diagnosed multiple myeloma (TIE-NDMM) remains challenging due to age, frailty, and comorbidities....
by MM360 Staff | Dec 13, 2025 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by MM360 Staff | Dec 12, 2025 | Publications
Diagnostics (Basel). 2025 Nov 21;15(23):2942. doi: 10.3390/diagnostics15232942. ABSTRACT After publication, the authors identified several errors in the manuscript, including inconsistencies between the manuscript’s reported results and the corresponding...
by MM360 Staff | Dec 12, 2025 | Publications
Cancers (Basel). 2025 Nov 21;17(23):3730. doi: 10.3390/cancers17233730. ABSTRACT BACKGROUND: Despite recent advances in the treatment of multiple myeloma (MM), the disease remains incurable. Agents targeting the programmed death-1 (PD-1) axis have become key...
by Marisa Wexler, MS | Dec 11, 2025 | Myeloma News
Treatment with the experimental medication eflornithine in combination with the approved chemotherapy Gleostine (lomustine) may help improve survival in people with aggressive astrocytoma carrying IDH mutations. That’s according to newly published results from a Phase...
